Monitor NASDAQ listing approval and final pricing. The IPO is existential — if it fails, the going-concern risk becomes acute. The 20% discount to OTC price suggests weak demand; any further discounting or delay would signal even weaker demand.
Executive Summary
Veri MedTech Holdings (VRHI) filed Amendment No. 8 to its S-1 IPO registration statement, maintaining the same core terms as prior amendments: a firm commitment offering of 3,750,000 shares at $4.00/share for gross proceeds of $15 million ($11.95M net). The company continues to experience declining revenue (~35% YoY in FY2025 to ~$10.8M, -28% in Q2 2026 to ~$2.0M), net losses, negative equity, and an auditor-identified going-concern risk that the IPO must resolve. The $4.00 offering price represents a ~20% discount to the recent OTC closing price of $5.00/share as of September 21, 2026, and the filing discloses substantial doubt about the company's ability to continue as a going concern without the IPO proceeds.
Key Facts
- Firm commitment offering of 3,750,000 shares at $4.00/share for gross proceeds of $15 million ($11.95M net).
- Revenue declined ~35% YoY in FY2025 to ~$10.8M from ~$16.7M; Q2 2026 revenue down ~28% YoY to ~$2.0M.
- Net loss of ~$2.32M in FY2025 and ~$496K in H1 2026; accumulated deficit of ~$5.34M at June 30, 2026.
- Stockholders' deficit of ~$2.73M and working capital deficit of ~$2.46M at June 30, 2026.
- Auditor raised substantial doubt about going concern; IPO proceeds are required for survival.
- Offering price of $4.00 is a ~20% discount to the $5.00 OTC closing price as of September 21, 2026.
- Series A Preferred Stock (100 shares) held by founders controls 80% of voting power; post-IPO, executives will hold >50% voting power.
- NASDAQ Capital Market listing application is a condition to closing the offering.
Financial Impact
IPO gross proceeds of $15M ($11.95M net) are critical to resolve going-concern risk; revenue decline of ~35% YoY and persistent net losses indicate fundamental deterioration.
Risk Factors
- IPO failure would trigger immediate going-concern risk; revenue continues to decline YoY; regulatory changes in key states (Florida, Florida and Colorado have materially reduced revenue; heavy reliance on Facebook/Google/Google advertising platforms; controlled company structure with founders control 80% voting power.
- relatedTickers: []
- timeHorizon:
- drugNames: []
- crossFilingNarrative:
- data:
- businessDescription:
- revenue:
- revenueGrowthPct:
- netIncome:
- useOfProceeds:
- proposedRange:
- comparables: []
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001096906-26-001407 |
| Document: vrhi_ex23z1.htm | 0001096906-26-001407 |
| Document: 0001096906-26-001407-index-headers.html | 0001096906-26-001407 |
| Document: 0001096906-26-001407-index.html | 0001096906-26-001407 |
| Document: 0001096906-26-001407.txt | 0001096906-26-001407 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 22, 2026 4w ago | S-1/A | $5.00 $4.41 | ▲ +11.80% | ▲ +12.49% | $4.41 (+11.80%) |
Sep 18, 2026 5w ago | S-1/A | $5.00 $4.41 | ▼ −11.80% | ▼ −10.89% | $4.41 (−11.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers